A meta-analysis of 20 randomized clinical trials (RCTs) including 10,645 women with estrogen receptor positive breast cancer demonstrated that, compared to no tamoxifen, adjuvant tamoxifen reduced breast cancer recurrence (relative risk (RR) 0.53, 95% CI: 0.47 to 0.59) and breast cancer mortality (RR 0.71, 95% CI: 0.61 to 0.81) at 5 years [5]. Here, ESR1 is linked to breast cancer.